Early trial explores new combo for Hard-to-Treat hepatitis c
NCT ID NCT00630058
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 22 times
Summary
This early-phase study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa 2b and ribavirin) in 20 people with chronic genotype 1b hepatitis C. The main goal was to check the safety and how the drug moves through the body, not to cure the disease. Participants had to have genotype 1b hepatitis C and could not have advanced liver scarring or other hepatitis infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, Japan
Conditions
Explore the condition pages connected to this study.